APA
De Divitiis C., von Arx C., Grimaldi A. M., Cicala D., Tatangelo F., Arcella A., Romano G. M., Simeone E., Iaffaioli R. V., Ascierto P. A. & Tafuto S. (20171016). Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine.
Chicago
De Divitiis C, von Arx C, Grimaldi A M, Cicala D, Tatangelo F, Arcella A, Romano G M, Simeone E, Iaffaioli R V, Ascierto P A and Tafuto S. 20171016. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine.
Harvard
De Divitiis C., von Arx C., Grimaldi A. M., Cicala D., Tatangelo F., Arcella A., Romano G. M., Simeone E., Iaffaioli R. V., Ascierto P. A. and Tafuto S. (20171016). Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine.
MLA
De Divitiis C, von Arx C, Grimaldi A M, Cicala D, Tatangelo F, Arcella A, Romano G M, Simeone E, Iaffaioli R V, Ascierto P A and Tafuto S. Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. : Journal of translational medicine. 20171016.